Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease

Cushing's Disease Clinical Trial

Official title:

The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04339751
• Other study ID #: 200019
• Secondary ID: 20-N-0019
• Status: Recruiting
• Phase: Phase 2
• Start date: June 16, 2024
• Est. completion date: December 1, 2024

Study information

• Verified date: September 29, 2023
• Source: National Institutes of Health Clinical Center (CC)
• Contact: Michaela X Cortes
• Phone: (301) 496-2921
• Email: michaela.cortes[@]nih.gov
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background: Cushing s disease is caused by excess ACTH hormone release by a benign tumor of the pituitary gland. It can lead to decreased quality of life and early death. The current best treatment for Cushing s disease is surgery. If surgery does not work or if the tumor returns, there are no more good treatment options. Vorinostat, which is approved to treat a type of lymphoma, might be a treatment option. Objective: To test vorinostat to see if it can kill tumor cells and change the number of hormones released in people with Cushing s disease. Eligibility: People ages 18 and older who have Cushing s disease and are scheduled for surgery under protocol 03-N-0164 to remove a tumor in their pituitary gland Design: Participants will be screened under protocol 03-N-0164. Participants will stay in the hospital for 8 days before their surgery. On the first day, participants will have a physical exam and blood tests. They will have their urine collected for testing all day. They will have an ECG: For this, small metal disks or sticky electrode pads will be placed on their chest to record heart activity. For the next 7 days, participants will have blood tests and all-day urine collection. They will drink at least 2 liters of fluid per day. They will take the study drug by mouth each morning. On the eighth day, participants will have their surgery. Leftover tissue will be collected for research. On the day they are discharged from the hospital, participants will have a physical exam and blood tests.

Description:

Study Description This is a single center, prospective pilot study of effectiveness of vorinostat to reduce midnight ACTH levels in patients with Cushing s Disease. Surgery for resection of ACTH producing pituitary adenoma will be offered at the NIH under another protocol (03-N-0164) as part of standard clinical care. Eligible subjects will be admitted to the Clinical Center for one week prior to surgery, during which time oral vorinostat will be administered daily. Objectives Cushing s disease is caused by excess ACTH hormone release by a benign tumor of the pituitary gland. The resulting increase in cortisol levels caused by increased ACTH causes a severe condition that leads to decreased quality of life and early death. The current best first treatment for Cushing s disease is surgery. However, if surgery is unsuccessful or if the tumor returns, there are no good treatment options for patients. In laboratory studies, we discovered that a previously FDA approved oral medication Vorinostat was able to kill tumors cells and reduce ACTH secretion. We want to test whether this drug can be used in patients with Cushing s disease to reduce ACTH levels. Primary Objective: to determine whether vorinostat reduces midnight plasma ACTH level Secondary Objectives: to evaluate the effect of vorinostat on urine cortisol levels Endpoints Primary Endpoint: midnight plasma ACTH level on the last day of drug administration. Secondary Endpoints: serum cortisol change during drug administration.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 22
• Est. completion date: December 1, 2024
• Est. primary completion date: December 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

• INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the

following criteria:

• Adult patients (18 years and older)
• Confirmed biochemical diagnosis of Cushing s disease (primary or recurrent) as evidenced by increased 24-hour urine free cortisol (UFC), normal or increased morning plasma Adrenocorticotropic Hormone (ACTH), and pituitary origin of excess ACTH.
• Surgical candidate for resection of ACTH producing pituitary adenoma
• Enrolled in 03-N-0164, Evaluation of Neurosurgical Disorders.
• Able to provide written informed consent at the time of study enrollment.
• Participants who are physically able to become pregnant must use an effective form of birth control from 14 days prior to enrollment through 6 months following the last dose of vorinostat. Participants who are able to father a child must use an effective form of birth control from Day 0 through 3 months following the last dose of vorinostat.

EXCLUSION CRITERIA:

• Patients who have been previously treated with vorinostat.
• Patients who have received sellar radiation.
• Significant medical illnesses that in the investigator s opinion cannot be adequately controlled or would compromise the patient s ability to tolerate this vorinostat.
• Any history of cancer, unless in complete remission and off of all therapy for that disease for a minimum of 3 years.
• History of thromboembolic disorder or deep vein thrombosis
• Presence of abnormal hematological and biochemical parameters, (such as anemia or

thrombocytopenia) as defined as:

• Neutrophil count < 1.5 K//micro L
• Hemoglobin < 8.0 g/dL.
• Hematocrit < 0.75x LLN (lower limit of normal)
• RBC count < 0.75x LLN
• Platelet count < 100 x 10^3 cells/micro L.
• Prothrombin time-international normalized ratio (PT-INR) > 1.5x ULN or Activated partial thromboplastin time (aPTT) > 1.5x ULN, with the exception of patients on prophylactic anticoagulation therapy
• Serum bilirubin level > 1.5x ULN.
• Active infection being currently treated with systemic antibiotics.
• Serious concurrent medical illness including renal failure (creatinine >3.0x - 6.0x ULN) liver failure (ALT/AST >5.0x - 20.0x ULN) or severe cardio-respiratory disease.
• Pregnancy or lactation.
• Presence of any disease that will obscure toxicity or dangerously alter drug metabolism (such as uncontrolled diabetes or bleeding disorders)
• Currently receiving other investigational agents.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat, such as valproate.
• Currently taking another HDACi, such as valproate.
• Currently taking coumadin or its derivative anticoagulants.
• Currently taking any other medication to reduce cortisol or ACTH levels

Related Conditions & MeSH terms

• ACTH-Secreting Pituitary Adenoma
• Adenoma
• Cushing's Disease
• Pituitary ACTH Hypersecretion
• Pituitary Neoplasms

Intervention

Drug:
• Vorinostat
Administration of Vorinostat

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2003 Dec;88(12):5593-602. doi: 10.1210/jc.2003-030871. — View Citation

Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). 1932. Obes Res. 1994 Sep;2(5):486-508. doi: 10.1002/j.1550-8528.1994.tb00097.x. No abstract available. — View Citation

Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet. 2006 May 13;367(9522):1605-17. doi: 10.1016/S0140-6736(06)68699-6. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Midnight Plasma ACTH	Relative change in midnight plasma ACTH. Dichotomized relative change using 20% as a cutoff (which is considered as clinical important): relative change >20% for reduction and relative change <=20% for no change).	Day -1, Day 0-1, Day 2, Day 4-6, Discharge
Secondary	Urinary Free Cortisol	Relative change in 24-hour urinary free cortisol during 7 day administration of Vorinostat	Day -1, Day 0-1, Day 2, Day 4-6, Discharge

External Links

•   NIH Clinical Center Detailed Web Page